某院2007-2009年乳腺癌内分泌治疗药利用评估  

Drug Utilization Evaluation of Endocrine Therapy for Breast Cancer in a Hospital from 2007 to 2009

作　　者：陈燕妮[1] 王俐[2] 陆澄[2] 刘小丰[2] 唐莲[1] 丁选胜[1] 

机构地区：[1]中国药科大学,南京市210009 [2]南京医科大学附属南京市妇幼保健院,南京市210004

出　　处：《中国药房》2011年第18期1659-1661,共3页China Pharmacy

摘　　要：目的:促进乳腺癌内分泌治疗药的合理应用。方法:依照《美国国立综合癌症网络乳腺癌临床实践指南(中国版)》和《中国抗癌协会乳腺癌诊治指南及规范(2008年版)》建立评价标准,采用药物利用评估法评价某院2007-2009年128例乳腺癌患者内分泌治疗药的应用情况。结果:128例乳腺癌患者中有44例(34.4%)用药与评价标准不符,属于不合理用药。其中有16例(12.5%)激素受体阳性患者未采用内分泌药治疗;有7例(5.5%)绝经前或围绝经期激素受体阳性患者应用第3代芳香化酶抑制剂治疗;有22例(17.2%)更换过内分泌治疗药。结论:该院乳腺癌内分泌治疗过程中存在不合理用药问题,临床医师应加强对治疗指南的学习,促进临床合理用药。OBJECTIVE：To promote the rational use of endocrine therapy drugs for breast cancer.METHODS：The evaluation criteria was established according to NCCN Clinical Practice Guidelines in Breast Cancer （Chinese version） and Chinese Anti-Cancer Association Breast Cancer Treatment Guidelines and Regulation （2008 version）.Drug utilization evaluation （DUE） method was used to evaluate the use of endocrine therapy drugs in 128 patients with breast cancer from 2007 to 2009.RESULTS：Among 128 patients with breast cancer,44 patients were not treated according to evaluation criteria （34.4%）.Endocrine therapy was not prescribed for 16 patients with endocrine-responsive disease （12.5%）;third-generation aromatase inhibitors were prescribed for 7 premenopausal or perimenopausal patients with endocrine-responsive disease （5.5%）;22 patients had altered endocrine therapy drugs （17.2%）.CONCLUSION：There are problems of irrational drug use during endocrine therapy for breast cancer.It is important for clinical doctors to study the treatment guidelines in order to promote the rational use of drugs.

关 键 词：乳腺癌 内分泌治疗 药物利用评估 合理用药 

分 类 号：R969.3[医药卫生—药理学] R287[医药卫生—药学]